James Davis

54PUBLICATIONS
163CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)ChiropracticGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (54)

|Jul 02, 2026
Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.

|May 18, 2026
Condensed vs. Standard Step-Up Dosing Schedule of Talquetamab in Relapsed/Refractory Multiple Myeloma.

|Mar 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Andrew J Portuguese, James A Davis, Shahzad Raza

|Feb 27, 2026
Discrepancy in Estimating GFR for Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant: A Retrospective Analysis.

Benjamin Teruel, Ashley L Golbus, Elaine Park

|Jan 16, 2026
Comparative Efficacy of Daratumumab Based Regimens in Patients With Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter Study.

Razan Mansour, Kimberly M Green, Chandler Graf

|Nov 28, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience.

Aimaz Afrough, Danai Dima, Beatrice Razzo

Pageof 9

Frequent Collaborators

20 joint publications

Jack Khouri

16 joint publications

Surbhi Sidana

16 joint publications

Larry D Anderson

15 joint publications

Danai Dima